vimarsana.com

Page 3 - Source Ucb Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022

First presentations from the BE OPTIMAL and BE COMPLETE studies evaluating bimekizumab in the treatment of adults with active psoriatic arthritis who were.

Bruxelles capitaleEimear obrienAntje witteJ clin pharmacolBrand communicationsCorporate communicationsUcb incDrug administrationAmerican college of rheumatologySource ucb incAmerican collegeSkin symptomsPsoriasis areaSeverity indexMinimal disease activityTotal sharp score

JAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA® (fenfluramine) Oral Solution in Lennox-Gastaut Syndrome (LGS)

Primary endpoint was met demonstrating that FINTEPLA, as adjunctive treatment, is effective in significantly reducing the frequency of drop seizures in LGS.

United statesBruxelles capitaleErica puntelNick francisKelly knuppAntje witteLaurent schotsUcb incDrug administrationZogenix incProgram see boxed warningGroup of companiesZogenix pressMajor concernsCorporate communicationsEuropean medicines agency

JAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA® (fenfluramine) Oral Solution in Lennox-Gastaut Syndrome (LGS)

Primary endpoint was met demonstrating that FINTEPLA, as adjunctive treatment, is effective in significantly reducing the frequency of drop seizur.

United statesBruxelles capitaleErica puntelNick francisKelly knuppAntje witteLaurent schotsUcb incDrug administrationZogenix incProgram see boxed warningGroup of companiesZogenix pressMajor concernsCorporate communicationsEuropean medicines agency

FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)

FINTEPLA® has demonstrated efficacy in the most difficult-to-treat seizure types,1,2 including drop seizures, which cause a person to suddenly lose muscle.

United statesBruxelles capitaleTracy dixon salazarMike davisErica puntelNick francisMinneap minnAntje witteLaurent schotsAmerican epilepsy societyUcb incZogenix incProgram see boxed warningGroup of companiesZogenix pressMajor concerns

New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting

Press release content from PR Newswire. The AP news staff was not involved in its creation.

United statesUnited kingdomNew havenBruxelles capitaleYale universityGreat britainBruce stroberEmmanuel caeymaexEimear obrienAntje witteImmunology solutionsBrand communicationsDrug administrationCentral connecticut dermatology researchAmerican academy of dermatologyEuropean union

vimarsana © 2020. All Rights Reserved.